Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease

OBJECTIVES: Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabay, Cem, Fautrel, Bruno, Rech, Jürgen, Spertini, François, Feist, Eugen, Kötter, Ina, Hachulla, Eric, Morel, Jacques, Schaeverbeke, Thierry, Hamidou, Mohamed A, Martin, Thierry, Hellmich, Bernhard, Lamprecht, Peter, Schulze-Koops, Hendrik, Courvoisier, Delphine Sophie, Sleight, Andrew, Schiffrin, Eduardo Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965361/
https://www.ncbi.nlm.nih.gov/pubmed/29472362
http://dx.doi.org/10.1136/annrheumdis-2017-212608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965361/
https://www.ncbi.nlm.nih.gov/pubmed/29472362
http://dx.doi.org/10.1136/annrheumdis-2017-212608

Ejemplares similares